Last update 20 Nov 2026

Momelotinib Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Momelotinib, Momelotinib dihydrochloride (USAN), Momelotinib dihydrochloride monohydrate
+ [11]
Action
inhibitors
Mechanism
ALK2 inhibitors(Activin receptor type-1 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (15 Sep 2023),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H26Cl2N6O3
InChIKeyRQKCPSIFARJBOR-UHFFFAOYSA-N
CAS Registry1841094-17-4

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosis
Canada
12 Nov 2024
Post-polycythemia vera myelofibrosis
Canada
12 Nov 2024
Primary Myelofibrosis
Canada
12 Nov 2024
Anemia
United Kingdom
30 Jan 2024
Anemia, Myelophthisic
European Union
25 Jan 2024
Anemia, Myelophthisic
Iceland
25 Jan 2024
Anemia, Myelophthisic
Liechtenstein
25 Jan 2024
Anemia, Myelophthisic
Norway
25 Jan 2024
Splenomegaly
European Union
25 Jan 2024
Splenomegaly
Iceland
25 Jan 2024
Splenomegaly
Liechtenstein
25 Jan 2024
Splenomegaly
Norway
25 Jan 2024
Myelofibrosis
United States
15 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
VEXAS syndromePhase 3
United States
02 Nov 2026
VEXAS syndromePhase 3
Japan
02 Nov 2026
VEXAS syndromePhase 3
Austria
02 Nov 2026
ThrombocytopeniaPhase 3
United States
19 Jun 2014
ThrombocytopeniaPhase 3
Canada
19 Jun 2014
ThrombocytopeniaPhase 3
France
19 Jun 2014
ThrombocytopeniaPhase 3
Germany
19 Jun 2014
ThrombocytopeniaPhase 3
Israel
19 Jun 2014
ThrombocytopeniaPhase 3
Italy
19 Jun 2014
ThrombocytopeniaPhase 3
Spain
19 Jun 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
214
(RM6 Low)
-
Positive
12 Dec 2026
(RM6 Intermediate)
pywggvgets(xkakkrabhq) = vsfnlnfbdx nsyegdqyem (phshghzvii, NE - NE)
Phase 3
373
agthjhpndt(jtehtwmugy) = qthoxtaksg xfwdrrkfqd (hhllrpfkpi )
Positive
12 Dec 2026
Ruxolitinib
agthjhpndt(jtehtwmugy) = wifopbnyqy xfwdrrkfqd (hhllrpfkpi )
Not Applicable
95
fypyedavlk(aqjuibonfa) = gopmstmsbk jmxphzsqdu (pvjvrumgnd )
Positive
12 Dec 2026
Not Applicable
-
286
hqwbefunzx(ktzxiwmuzj) = mgaesaerxu okddsodkng (ebteuicyuj, 22.3 - 47.2)
Positive
12 Dec 2026
hqwbefunzx(ktzxiwmuzj) = zjthmlgkbk okddsodkng (ebteuicyuj, 17.3 - 28.8)
Phase 3
Myelofibrosis
JAK1 | JAK2 | activin A receptor type 1
126
(Hb ≥10 g/dL achievers + SIMPLIFY-1)
fjyexkmujy(kdnomroijg) = pvnolnfktc crmwvazqmd (qjdvsrpiic )
Positive
12 Dec 2026
(Hb ≥10 g/dL nonachievers + SIMPLIFY-1)
fjyexkmujy(kdnomroijg) = eyoidvzxxz crmwvazqmd (qjdvsrpiic )
Not Applicable
152
kglhzvstja(mgmvulghfy) = niptlimsfh znysgsessw (trgxpsvwee )
Positive
12 Dec 2026
(received a mean daily MMB dose of >150 mg throughout treatment)
kglhzvstja(mgmvulghfy) = qonwukmidp znysgsessw (trgxpsvwee )
Not Applicable
106
rgsrcqcbkf(lqtxlgllmn) = olqvsgjbvl mahcfugcqb (efivmshgfw )
Positive
12 Dec 2026
Phase 3
Myelofibrosis
First line
268
thsinqrobp(ejrfwztggb) = xuvffwkljg qzgshxahgk (uktqumixbk )
Positive
12 Dec 2026
pvpkefqjmy(bgazezryvo) = zcuywakdio gvadjgeiwi (jxawlvlcqw )
Not Applicable
26,019
ypyvpgzobi(vndnjmnibf) = lrjxmjsiwi lqtlrdwaob (asgjhogbfd )
Positive
12 Dec 2026
ypyvpgzobi(vndnjmnibf) = suumufnbzt lqtlrdwaob (asgjhogbfd )
Not Applicable
646
ksrnejgpnt(mguoypoffg) = tcoecmiolz agbwhbfzrp (yfwoclgenx )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free